USD 1.0
(8.7%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -8.52 Million USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -1.76 Million USD | 79.26% |
2024 Q2 | -1.73 Million USD | 2.12% |
2023 Q1 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 FY | -8.52 Million USD | 0.0% |
2023 Q4 | -8.52 Million USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2020 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Amgen Inc. | 19.73 Billion USD | 100.043% |
AstraZeneca PLC | 37.54 Billion USD | 100.023% |
Biogen Inc. | 7.3 Billion USD | 100.117% |
Gilead Sciences, Inc. | 21.14 Billion USD | 100.04% |
Scilex Holding Company | 31.06 Million USD | 127.448% |
Scilex Holding Company | 31.06 Million USD | 127.448% |